NI201200089A - INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. - Google Patents

INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.

Info

Publication number
NI201200089A
NI201200089A NI201200089A NI201200089A NI201200089A NI 201200089 A NI201200089 A NI 201200089A NI 201200089 A NI201200089 A NI 201200089A NI 201200089 A NI201200089 A NI 201200089A NI 201200089 A NI201200089 A NI 201200089A
Authority
NI
Nicaragua
Prior art keywords
acetyl
coa carboxylase
pyrazolospiroketone
inhibitors
compound
Prior art date
Application number
NI201200089A
Other languages
English (en)
Inventor
Andrew Grffith David
Wei-Shung Kung Daniel
William Bagley Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NI201200089A publication Critical patent/NI201200089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un compuesto de Fórmula (1) o una sal farmacéuticamente aceptable del compuesto, en la que R1, R2, R3 y R4 son como se describen en el presente documento; composiciones farmacéuticas del mismo; y el uso del mismo en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una(s) enzima(s) acetil - CoA carboxilasa(s) en un animal.
NI201200089A 2009-11-10 2012-05-09 INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. NI201200089A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10

Publications (1)

Publication Number Publication Date
NI201200089A true NI201200089A (es) 2012-08-20

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200089A NI201200089A (es) 2009-11-10 2012-05-09 INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.

Country Status (39)

Country Link
US (4) US8288405B2 (es)
EP (3) EP2947082A1 (es)
JP (1) JP5114610B1 (es)
KR (2) KR101550557B1 (es)
CN (1) CN102695708B (es)
AP (1) AP3283A (es)
AR (1) AR078944A1 (es)
AU (1) AU2010317501B2 (es)
BR (1) BR112012011072A2 (es)
CA (1) CA2778886C (es)
CL (1) CL2012000999A1 (es)
CO (1) CO6541569A2 (es)
CR (1) CR20120190A (es)
CU (1) CU24077B1 (es)
DK (1) DK2499139T3 (es)
DO (1) DOP2012000128A (es)
EA (1) EA020153B1 (es)
EC (1) ECSP12011880A (es)
ES (1) ES2444543T3 (es)
GE (1) GEP20146169B (es)
HN (1) HN2012000973A (es)
HR (1) HRP20140025T1 (es)
IL (1) IL219373A (es)
MA (1) MA33734B1 (es)
MX (1) MX2012005429A (es)
NI (1) NI201200089A (es)
NZ (1) NZ599815A (es)
PE (1) PE20121469A1 (es)
PH (1) PH12012500903A1 (es)
PL (1) PL2499139T3 (es)
PT (1) PT2499139E (es)
RS (1) RS53156B (es)
SI (1) SI2499139T1 (es)
TN (1) TN2012000192A1 (es)
TW (1) TWI394756B (es)
UA (1) UA102336C2 (es)
UY (1) UY33020A (es)
WO (1) WO2011058474A1 (es)
ZA (1) ZA201204231B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144554A1 (en) 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011058474A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
HRP20161178T1 (hr) * 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
BR112013010310A2 (pt) 2010-10-29 2016-11-29 Pfizer inibidores de acetil-coa carboxilase de lactama n1/n2
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MY162167A (en) * 2011-04-22 2017-05-31 Pfizer Substituted acetyl-coa carboxylase inhibitors
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
ES2731773T3 (es) 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
HK1217448A1 (zh) 2013-09-12 2017-01-13 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用於治疗寻常痤疮的用途
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
BR112017005128A2 (pt) 2014-09-16 2018-07-31 Celgene Quanticel Res Inc inibidores de histona desmetilase
MX2017003463A (es) * 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
CN107002262B (zh) 2014-11-10 2019-10-29 国立大学法人横浜国立大学 氧气发生用阳极
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US11541046B2 (en) 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds
FI3713942T3 (fi) 2017-11-21 2023-05-04 Pfizer 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
US12521375B2 (en) 2020-05-21 2026-01-13 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
AU2023316863A1 (en) * 2022-07-29 2025-02-13 Pfizer Inc. Novel acc inhibitors
WO2025133948A1 (en) * 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
UA84208C2 (en) 2004-05-25 2008-09-25 Пфайзер Продактс Инк. Tetraazabenzo(e)azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
MX2008000966A (es) 2005-07-19 2008-03-26 Merck & Co Inc Nuevos derivados de espirocromanona.
US20100160255A1 (en) * 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EA200900613A1 (ru) * 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2195321B1 (en) * 2007-04-12 2016-10-19 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c
WO2009014455A1 (en) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Email response time expectation system
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2009144554A1 (en) * 2008-05-28 2009-12-03 Pfizer, Inc. Pyrazolospiroketone acetyl-c0a carboxylase inhibitors
US20110009443A1 (en) * 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
US8110570B2 (en) * 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
WO2010044981A2 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2011058474A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2499140A1 (en) 2009-11-10 2012-09-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
MY162167A (en) * 2011-04-22 2017-05-31 Pfizer Substituted acetyl-coa carboxylase inhibitors

Also Published As

Publication number Publication date
CO6541569A2 (es) 2012-10-16
GEP20146169B (en) 2014-09-25
HN2012000973A (es) 2015-03-02
CU24077B1 (es) 2015-03-30
DOP2012000128A (es) 2012-08-31
JP5114610B1 (ja) 2013-01-09
HK1173724A1 (en) 2013-05-24
CR20120190A (es) 2012-05-24
BR112012011072A2 (pt) 2017-06-20
UA102336C2 (uk) 2013-06-25
US8288405B2 (en) 2012-10-16
EP2676958A1 (en) 2013-12-25
MX2012005429A (es) 2012-06-19
KR101478517B1 (ko) 2015-01-02
TW201127838A (en) 2011-08-16
IL219373A0 (en) 2012-06-28
TWI394756B (zh) 2013-05-01
AP2012006269A0 (en) 2012-06-30
EP2499139A1 (en) 2012-09-19
EA201290191A1 (ru) 2012-12-28
HRP20140025T1 (hr) 2014-02-14
MA33734B1 (fr) 2012-11-01
US20130296319A1 (en) 2013-11-07
DK2499139T3 (da) 2014-01-27
EP2499139B1 (en) 2013-12-11
PE20121469A1 (es) 2012-11-01
AU2010317501A1 (en) 2012-05-17
ECSP12011880A (es) 2012-07-31
CU20120071A7 (es) 2013-05-31
IL219373A (en) 2014-04-30
US20140288111A1 (en) 2014-09-25
US8507681B2 (en) 2013-08-13
KR101550557B1 (ko) 2015-09-04
SI2499139T1 (sl) 2014-01-31
US20110111046A1 (en) 2011-05-12
US20130030181A1 (en) 2013-01-31
CA2778886C (en) 2014-01-07
CN102695708A (zh) 2012-09-26
RS53156B (sr) 2014-06-30
AP3283A (en) 2015-05-31
EA020153B1 (ru) 2014-09-30
EP2947082A1 (en) 2015-11-25
AU2010317501B2 (en) 2013-06-06
KR20120099460A (ko) 2012-09-10
CA2778886A1 (en) 2011-05-19
ZA201204231B (en) 2013-02-27
EP2676958B1 (en) 2015-07-01
ES2444543T3 (es) 2014-02-25
WO2011058474A8 (en) 2012-04-26
NZ599815A (en) 2013-04-26
PT2499139E (pt) 2014-02-10
PL2499139T3 (pl) 2014-04-30
US9139587B2 (en) 2015-09-22
US8802690B2 (en) 2014-08-12
WO2011058474A1 (en) 2011-05-19
JP2013510192A (ja) 2013-03-21
TN2012000192A1 (fr) 2013-12-12
UY33020A (es) 2011-06-30
AR078944A1 (es) 2011-12-14
KR20140034919A (ko) 2014-03-20
CN102695708B (zh) 2014-10-15
PH12012500903A1 (en) 2014-09-24
CL2012000999A1 (es) 2012-07-20

Similar Documents

Publication Publication Date Title
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
UY32730A (es) Inhibidores de cyp17
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ECSP12011961A (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
DOP2012000078A (es) Derivados de espirolactama y usos de los mismos
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
CY1114907T1 (el) N1-πυραζολοσπειροκετονης αναστολεις ακετυλ-coa καρβοξυλασης
TH129189A (th) ตัวยับยั้ง N1-ไพแรโซโลสไพโรคีโทน แอเซทิล-CoAคาร์บอกซิเลส
HN2012000132A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos